|Bid||0.00 x 1400|
|Ask||7.50 x 1100|
|Day's Range||5.84 - 7.78|
|52 Week Range||3.07 - 9.60|
|Beta (3Y Monthly)||2.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aravive (ARAV) delivered earnings and revenue surprises of 51.79% and 205.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Houston-based company said it had a loss of 42 cents. The biopharmaceutical company posted revenue of $1.7 million in the period. Aravive shares have climbed 82% since the beginning ...
A look at the shareholders of Aravive, Inc. (NASDAQ:ARAV) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders...
Versartis Inc is an endocrine-focused biopharmaceutical company initially developing long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. Warning! GuruFocus has detected 1 Warning Sign with ARAV.
Jay Shepard has been the CEO of Aravive, Inc. (NASDAQ:ARAV) since 2015. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we'll consider growth thatRead More...
The Menlo Park, California-based company said it had a loss of $1.08 per share. Versartis shares have declined 54 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares ...